The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects ...

The positive opinion, announced on April 25, 2025, supports the use of Amvuttra in treating both wild-type and hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Vutrisiran is already approved as Amvuttra to treat rare disease hereditary ATTR amyloidosis, so approval in Stargardt disease would prompt the pricing negotiation mechanism. Alnylam's earlier ...